Insights & Analysis

Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

Page 18

M&A

Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss

By David Marcus
|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.
M&A

Drinks With The Deal: Mintz's Matthew Simpson

By David Marcus
|
Published: October 1st, 2021
The Mintz partner discusses his transition from peace negotiator to M&A lawyer, why he enjoys the middle market, what he's learned from advising reps and warranties insurers and how he finds serenity on sailboats in the latest edition of Drinks With The Deal.
Podcasts

Behind the Buyouts: EQT's Brown Pivots From Microsoft to EU Tech

By Steve Gelsi
|
Published: September 29th, 2021
EQT Growth head Marc Brown said EQT's desire as a firm to do well financially while promoting diversity and inclusion appealed to him as he looked to start a new phase of his career after 20 years working on M&A deals at Microsoft.
Podcasts

Fresh Start: Hilco's Ian Fredericks

By Stephanie Gleason
|
Published: September 16th, 2021
The Hilco Merchant Resources president discusses the business of liquidation and the outlook for retail in the fourth quarter.
M&A

Drinks With The Deal: NYU's Rob Jackson and Yale's John Morley

By David Marcus
|
Published: September 16th, 2021
Rob Jackson, a former SEC commissioner and current NYU Law professor, and John Morley, a professor at Yale Law School, say SPACs should be treated more stringently by the SEC and discuss their current research projects.
M&A

Drinks With The Deal: Freshfields' Ethan Klingsberg

By David Marcus
|
Published: August 19th, 2021
Ethan Klingsberg, head of U.S. corporate and M&A at Freshfields, discusses the pressures that increased antitrust scrutiny has put on dealmaking and how companies can respond.